

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:
201655Orig1s000

OTHER REVIEW(S)

**Department of Health and Human Services
Public Health Service
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Surveillance and Epidemiology
Office of Medication Error Prevention and Risk Management**

PATIENT LABELING REVIEW

Date: October 03, 2011

To: Bob Rappaport MD, Director
Division of Anesthesia, Analgesia and Addiction Products (DAAAP)

Through: LaShawn Griffiths, MSHS-PH, BSN, RN
Acting Team Leader, Patient Labeling Reviewer
Division of Risk Management (DRISK)
Barbara Fuller, RN, MSN, CWOCN
Acting Team Leader, Patient Labeling Reviewer
Division of Risk Management

From: Steve L. Morin, RN, BSN, OCN
Patient Labeling Reviewer
Division of Risk Management

Subject: DRISK Review of Patient Labeling (Medication Guide)

Drug Name (established name): OPANA ER (oxymorphone hydrochloride)

Dosage Form and Route: Extended-Release tablets, CII

Application Type/Number: NDA 201-655

Applicant: Endo Pharmaceuticals Inc.

OSE RCM #: 2011-2447

1 INTRODUCTION

This review is written in response to a request by the Division of Anesthesia, Analgesia and Addiction Products (DAAAP) for the Division of Risk Management (DRISK) to review the Applicant's proposed Medication Guide (MG) for OPANA ER (oxymorphone hydrochloride) Extended-Release tablets. The proposed indication for OPANA is for the relief of moderate to severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time.

On July 7, 2010 Endo Pharmaceuticals submitted New Drug Application (NDA) 201-655 for (b) (4) (oxymorphone hydrochloride) Extended-Release Tablets. DRISK completed a review of the proposed Medication Guide on December 22, 2010. On January 6 2011 Endo Pharmaceuticals (b) (4) submitted a request for the proposed proprietary tradename OPANA ER. On January 7, 2011 Endo received a Complete Response for bioequivalence study deficiencies. On June 13, 2011 Endo Pharmaceuticals submitted a Class 2 Resubmission for OPANA ER (oxymorphone hydrochloride) Extended-Release Tablets.

The proposed REMS was reviewed by DRISK and submitted to DAAAP under separate cover on August 31, 2011.

2 MATERIAL REVIEWED

- Draft OPANA ER (oxymorphone hydrochloride) Extended-Release tablets Medication Guide (MG) received on June 13, 2011 and sent to DRISK on September 19, 2011.
- Draft OPANA ER (oxymorphone hydrochloride) Extended-Release tablets Prescribing Information (PI) received June 13, 2011 and sent to DRISK on September 19, 2011.

3 REVIEW METHODS

To enhance patient comprehension, materials should be written at a 6th to 8th grade reading level, and have a reading ease score of at least 60%. A reading ease score of 60% corresponds to an 8th grade reading level. In our review of the MG the target reading level is at or below an 8th grade level.

Additionally, in 2008 the American Society of Consultant Pharmacists Foundation (ASCP) in collaboration with the American Foundation for the Blind (AFB) published *Guidelines for Prescription Labeling and Consumer Medication Information for People with Vision Loss*. The ASCP and AFB recommended using fonts such as Verdana, Arial or APhont to make medical information more accessible for patients with vision loss. We have reformatted the MG document using the Verdana font, size 11.

In our review of the MG we have:

- simplified wording and clarified concepts where possible
- ensured that the MG is consistent with the Prescribing Information (PI)

- removed unnecessary or redundant information
- ensured that the MG meets the Regulations as specified in 21 CFR 208.20
- ensured that the MG meets the criteria as specified in FDA's Guidance for Useful Written Consumer Medication Information (published July 2006)

4 CONCLUSIONS

The MG is acceptable with our recommended changes.

5 RECOMMENDATIONS

- Please send these comments to the Applicant and copy DRISK on the correspondence.
- Our annotated versions of the MG are appended to this memo. Consult DRISK regarding any additional revisions made to the PI to determine if corresponding revisions need to be made to the MG.

Please let us know if you have any questions.

16 pages of draft labeling has been withheld in full as

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

STEVE L MORIN
10/03/2011

LASHAWN M GRIFFITHS
10/03/2011

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.